



# MEDICO REMEDIES LTD.

A WHO-GMP, ISO 9001-2015 & GOVT. RECOGNISED STAR EXPORT HOUSE

Manufacturers of Pharmaceutical Formulations



CIN : L24230MH1994PLC077187  
GSTIN - 27AABCM8349L1ZY.

Regd. Office : 1105/1106, Hubtown Solaris, N. S. Phadke Marg, Opp. Teligali, Andheri - East, Mumbai - 400 069. • Tel. : +91-22-2682 1054 / 1055 / 2683 7116

Email : medicoremedies@yahoo.com • info@medicoremedies.com • Website : www.medicoremediesindia.com • www.medicoremediesindia.net • www.tabletandcapsules.com

May 24, 2022

To,  
Bombay Stock Exchange Limited,  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai-400001.

**Scrip Code: 540937**

**SUB: MIGRATION OF EQUITY SHARES OF MEDICO REMEDIES LIMITED FROM SME PLATFORM OF BSE LIMITED (BSE SME) TO MAIN BOARD OF BSE LIMITED AND NSE LIMITED**

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that BSE has issued the circular for the migration vide circular no. 20220524-10 dated May 24, 2022 stating that Company will be migrated & admitted to dealings on the Main Board of Bombay Stock Exchange Limited with effect from Thursday, May 26, 2022.

Simultaneously, we have also received the letter from National Stock Exchange of India Limited dated May 24, 2022 stating, that equity shares of the Company shall be listed and admitted to dealings on NSE Limited with effect from Thursday, May 26, 2022.

We are enclosing herewith both the circulars.

We request you to kindly take the same on your record

Thanking You,

For **Medico Remedies Limited**

Harshit  
Haresh  
Mehta

Harshit Mehta  
(Managing Director)

Factory : 7, 8 & 9, Dewan & Sons Udyog Nagar, Lokmanya Nagar, Palghar (W), Dist. Palghar - 401 404, Maharashtra.

Tel : +91 2525-255287 / 256381 • Fax : +91 2525-255287

NOTICES

Notice No. 20220524-10 Notice Date 24 May 2022  
 Category Company related Segment SME  
 Subject Migration of Equity Shares of Medico Remedies Limited from BSE SME Platform to BSE Mainboard Platform  
 Attachments [Annexure I.pdf](#) ; [Annexure II.pdf](#) ;  
 Content

Trading Members of the Exchange are hereby informed that effective from **Thursday, May 26, 2022**, the equity shares of **Medico Remedies Limited** which are already listed under BSE SME Platform will now be migrated & admitted to dealings on the Mainboard Platform in the list of 'B' Group.

<b>Name of the Company</b>	<b>Medico Remedies Limited</b>
<b>Registered Office</b>	1105/1106, 11th Floor, Hubtown Solaris Opp. Telli Galli, N S Phadke Marg, Andheri East, Mumbai -400069 Tel. No.- +91 22 2670 1055/66 Email: <a href="mailto:info@medicoremedies.com">info@medicoremedies.com</a>  Website: <a href="http://www.medicoremedies.com">www.medicoremedies.com</a>
<b>Securities</b>	1,65,96,800 Equity Shares of Rs.10/- each fully paid-up
<b>Distinctive numbers</b>	1 to 16596800
<b>Market Lot</b>	One Share
<b>Scrip Code</b>	540937
<b>Abbreviated Name on BOLT System</b>	MEDICO
<b>Scrip ID on BOLT System</b>	MEDICO
<b>ISIN No.</b>	INE630Y01016



- Trading Members may note that as per the guidelines issued by SEBI dated February 16, 2000, securities of the company will only be traded in Dematerialized form. Trades effected in this scrip will be in unit market lot (i.e., one share).
- The Audited financial result of the Company for the half year ended March 31, 2022, is enclosed as **Annexure I**.
- A copy of the shareholding pattern as on March 31, 2022, submitted by the company is enclosed as **Annexure II**.

4. The company's financial year ending is March 31.
5. Subsequent to the migration, the Market Maker to the Company in the BSE SME Platform, **Aryaman Capital Markets Limited** will cease to continue as Market Maker to the Company
6. The address of the Registrar and Transfer Agent of the Company is given below:
- Cameo Corporate Services Limited**  
Subramanian Building No. 1,  
Club House Road, Chennai, Tamil Nadu, 600002
- Contact Person:** Mr. R. D. Ramasamy  
**Telephone No:** 044 2846 0390/ 1989
7. In case members require any clarifications on the subject matter of this Notice, they may please contact any of the following:

<b>A) At the Company:</b> Mr. Dinesh Modi Company Secretary and Compliance Officer	<b>Address:</b> 1105/1106, 11th Floor, Hubtown Solaris Opp. Telli Galli, N S Phadke Marg, Andheri East, Mumbai -400069 <b>Tel. No. -</b> +91 22 2670 1055/66 <b>Email:</b> <a href="mailto:info@medicoremedies.com">info@medicoremedies.com</a> <b>Website:</b> <a href="http://www.medicoremedies.com">www.medicoremedies.com</a>
<b>B) At the Exchange:</b> Raghavendra Bhat Deputy Manager	<b>Tel.:</b> 022-22728915



**Rupal Khandelwal**  
Assistant General Manager  
Monday, May 23, 2022



**National Stock Exchange Of India Limited**

Ref: NSE/LIST/ 19

May 24, 2022

The Company Secretary  
Medico Remedies Limited  
1105, Hubtown Solaris  
N.S. Phadke Marg  
Sai Wadi, Near Fly over Bridge  
Maharashtra-400069.

**Kind Attn: Mr. Dinesh Navnitlal Modi**

Dear Sir,

**Re.: Listing of Equity Shares of Medico Remedies Limited pursuant to Migration from SME Platform of BSE to Capital Market Segment (Main Board) of National Stock Exchange of India Limited**

We refer to your application for listing and trading in equity shares of the Company on Capital Market Segment (Main Board) of National Stock Exchange of India Limited. We are pleased to inform you that the equity shares of the Company shall be listed and admitted to dealings on the Exchange (Capital Market Segment) w.e.f. May 26, 2022 pursuant to Migration from SME Platform of BSE as per the details given below:

Sr. No.	Description of Securities	Symbol	Series	No. of Securities	Mkt. Lot	Distinctive Numbers
1.	Equity shares of Rs. 10/- each fully paid up	MEDICO	EQ	16596800	1	1-16596800

You are requested to mention the symbol and series in all future correspondence. All important information submitted by you pursuant to the various Regulations of SEBI (LODR), 2015 shall be broadcast through our nationwide network to the trading members.

Please note that all critical/price sensitive information and other submissions under SEBI (LODR) Regulation, 2015 shall be provided by the company through online filing facilities provided by the Exchange in electronic platform 'NEAPS'- NSE Electronic Application Processing System (<https://neaps.nseindia.com/NEWLISTINGCORP/>) for quicker and efficient processing of your submissions.

The company shall ensure submission of financial results in accordance with Reg. 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 if migrated after the end of quarter but before due date for submission of said financial results.

If you require any further clarifications, we shall be glad to oblige.

**Yours faithfully,**  
**For National Stock Exchange of India Limited**

**Jiten Patel**  
**Manager**



This Document is Digitally Signed



Signer: Jiten Bharat Patel  
Date: Tue, May 24, 2022 13:42:39 IST  
Location: NSE